Reduced survival in patients with ALS with upper airway obstructive events on non-invasive ventilation

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1045-50. doi: 10.1136/jnnp-2015-312606. Epub 2016 Apr 18.

Abstract

Introduction: Non-invasive ventilation (NIV) is part of standard care in amyotrophic lateral sclerosis (ALS). Intolerance or unavailability of NIV, as well as the quality of correction of nocturnal hypoventilation, has a direct impact on prognosis.

Objectives: We describe the importance of NIV failure due to upper airway obstructive events, the clinical characteristics, as well as their impact on the prognosis of ALS.

Methods: Retrospective analysis of the data of 190 patients with ALS and NIV in a single centre for the period 2011-2014. 179 patients tolerating NIV for more than 4 h per night without leaks were analysed.

Results: Among the 179 patients, after correction of leaks, 73 remained inadequately ventilated at night (defined as more than 5% of the night spent at <90% of SpO2), as a result of obstructive events in 67% of cases (n=48). Patients who remained inadequately ventilated after optimal adjustment of ventilator settings presented with shorter survival than adequately ventilated patients. Unexpectedly, patients with upper airway obstructive events without nocturnal desaturation and in whom no adjustment of treatment was therefore performed also presented with shorter survival. On initiation of NIV, no difference was demonstrated between patients with and without upper airway obstructive events. In all patients, upper airway obstruction was concomitant with reduction of ventilatory drive.

Conclusions: This study shows that upper airway obstruction during NIV occurs in patients with ALS and is associated with poorer prognosis. Such events should be identified as they can be corrected by adjusting ventilator settings.

Publication types

  • Observational Study
  • Webcast

MeSH terms

  • Aged
  • Airway Obstruction / mortality*
  • Airway Obstruction / therapy*
  • Amyotrophic Lateral Sclerosis / mortality*
  • Amyotrophic Lateral Sclerosis / therapy*
  • Combined Modality Therapy
  • Comorbidity
  • Female
  • Hospitals, University
  • Humans
  • Male
  • Middle Aged
  • Noninvasive Ventilation*
  • Oxygen / blood
  • Polysomnography
  • Prognosis
  • Respiratory Insufficiency / mortality
  • Respiratory Insufficiency / therapy
  • Retrospective Studies
  • Riluzole / therapeutic use
  • Survival Analysis

Substances

  • Riluzole
  • Oxygen